Weekly Research Analyst Ratings Updates for Turning Point Therapeutics (TPTX)


A number of companies have changed their ratings and price targets on the shares of Turning Point Therapeutics (NASDAQ: TPTX) recently:

  • 05/20/2022 – Turning Point Therapeutics is now covered by analysts at Bank of America Co. They have set a “buy” rating and a price target of $58.00 for the stock.
  • 05/11/2022 – Turning Point Therapeutics has been upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Turning Point Therapeutics is a clinical-stage biopharmaceutical company that designs and develops novel, targeted small molecule oncology therapies to address key limitations of existing therapies and improve the lives of patients. Their in-house developed and 100% owned portfolio of next-generation tyrosine kinase inhibitors (TKIs) targets numerous cancer genetic factors in naïve and TKI-experienced patients. The pervasive challenges of intrinsic and acquired resistance to treatment often limit the response rate and durability of existing therapies. One such challenge is the emergence of solvent front mutations, which are a common cause of acquired resistance to currently approved therapies for ROS1, TRK, and ALK kinases. They developed a macrocycle platform allowing us to design proprietary small and compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. “
  • 5/11/2022 – Turning Point Therapeutics has had its price target lowered by Wedbush analysts from $93.00 to $61.00.
  • 04/05/2022 – Turning Point Therapeutics has been downgraded by analysts at Zacks Investment Research from a “Hold” rating to a “Sell” rating. According to Zacks, “Turning Point Therapeutics is a clinical-stage biopharmaceutical company that designs and develops novel, targeted small molecule oncology therapies to address key limitations of existing therapies and improve the lives of patients. Their in-house developed and 100% owned portfolio of next-generation tyrosine kinase inhibitors (TKIs) targets numerous cancer genetic factors in naïve and TKI-experienced patients. The pervasive challenges of intrinsic and acquired resistance to treatment often limit the response rate and durability of existing therapies. One such challenge is the emergence of solvent front mutations, which are a common cause of acquired resistance to currently approved therapies for ROS1, TRK, and ALK kinases. They developed a macrocycle platform allowing us to design proprietary small and compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. “
  • 03/22/2022 – Turning Point Therapeutics has had its price target lowered by HC Wainwright analysts from $162.00 to $161.00. They now have a “buy” rating on the stock.

Turning Point Therapeutics stock traded down $0.26 during Friday’s trading, hitting $35.10. 17,735 shares of the company were traded, against an average volume of 723,195. The company’s 50-day moving average is $29.56 and its 200-day moving average is $35.62. Turning Point Therapeutics, Inc. has a 52-week low of $23.77 and a 52-week high of $83.06. The company has a market capitalization of $1.74 billion, a P/E ratio of -6.31 and a beta of 0.86.

Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last reported quarterly results on Tuesday, May 10. The company reported ($1.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.51) by $0.01. The company had revenue of $0.40 million for the quarter. The company’s quarterly revenue was down 98.4% from the same quarter last year. During the same period of the previous year, the company achieved EPS of ($0.73). Stock analysts expect Turning Point Therapeutics, Inc. to post earnings per share of -6.79 for the current fiscal year.

Major investors have recently changed their positions in the company. The Manufacturers Life Insurance Company increased its position in shares of Turning Point Therapeutics by 113.8% during the first quarter. The Manufacturers Life Insurance Company now owns 50,332 shares of the company valued at $1,355,000 after purchasing an additional 26,787 shares in the last quarter. Walleye Capital LLC bought a new stock position in Turning Point Therapeutics during Q1 worth $606,000. Virtu Financial LLC bought a new stock position in Turning Point Therapeutics during Q1 worth $237,000. Point72 Hong Kong Ltd bought a new position in shares of Turning Point Therapeutics during Q1 worth $96,000. Finally, Quantbot Technologies LP bought a new position in shares of Turning Point Therapeutics during the 1st quarter at a value of $267,000. Hedge funds and other institutional investors own 90.33% of the company’s shares.

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, is committed to the design and development of therapies that target the genetic factors of cancer. It is developing a portfolio of tyrosine kinase inhibitors (TKIs) that target cancer genetic factors in TKI-naïve and TKI-pretreated patients.

Featured articles



Receive daily news and reviews for Turning Point Therapeutics Inc. – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Turning Point Therapeutics Inc and related companies with MarketBeat.com’s FREE daily newsletter.

Comments are closed.